KURA has been the subject of several other research reports. Cann reaffirmed an outperform rating and issued a $18.00 price target on shares of Kura Oncology in a research report on Monday, March 6th. Zacks Investment Research raised shares of Kura Oncology from a hold rating to a buy rating and set a $10.00 price target for the company in a research report on Thursday, May 18th.
Shares of Kura Oncology (NASDAQ:KURA) opened at 7.20 on Wednesday. The stock’s market cap is $141.60 million. Kura Oncology has a one year low of $2.50 and a one year high of $12.10. The stock has a 50 day moving average of $8.85 and a 200 day moving average of $7.86.
Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Monday, May 15th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.05. On average, analysts forecast that Kura Oncology will post ($1.63) EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Kura Oncology, Inc. (KURA) PT Set at $16.00 by Oppenheimer Holdings, Inc.” was first published by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/2654517/kura-oncology-inc-kura-pt-set-at-16-00-by-oppenheimer-holdings-inc.html.
Large investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC raised its stake in Kura Oncology by 25.4% in the fourth quarter. Renaissance Technologies LLC now owns 30,600 shares of the company’s stock valued at $181,000 after buying an additional 6,200 shares during the last quarter. First Republic Investment Management Inc. acquired a new stake in Kura Oncology during the fourth quarter valued at approximately $174,000. Nationwide Fund Advisors bought a new position in shares of Kura Oncology during the first quarter worth about $136,000. Alethea Capital Management LLC increased its position in shares of Kura Oncology by 31.8% in the first quarter. Alethea Capital Management LLC now owns 84,769 shares of the company’s stock worth $746,000 after buying an additional 20,469 shares during the period. Finally, Segantii Capital Management Ltd bought a new position in shares of Kura Oncology during the first quarter worth about $120,000. 50.19% of the stock is owned by hedge funds and other institutional investors.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.